Multicentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster.

Overview

Since December 2019, a new agent, the coronavirus SARS-Cov-2, has spread from China to the rest of the world causing an international epidemic of respiratory diseases called COVID-19. Oise was one of the first clusters in France, with more than 4,000 confirmed cases. A significant proportion (80%) of patients with COVID-19 are ambulatory. However, few data are available for this particular population in France. Thus, few clear recommendations are available. We propose to conduct a large cohort of observation of suspected or confirmed COVID-19 patients on an ambulatory basis in the Oise region. This observatory will make it possible to describe the epidemiological characteristics and initial management of COVID-19 patients and to identify early severity factors.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Other
  • Study Primary Completion Date: June 30, 2020

Interventions

  • Other: observational
    • observational management of outpatients COVID 19

Arms, Groups and Cohorts

  • outpatients COVID 19 positive

Clinical Trial Outcome Measures

Primary Measures

  • clinical description of covid 19 ambulatory cases.
    • Time Frame: 3 months

Secondary Measures

  • Biological and radiological description of ambulatory cases
    • Time Frame: 3 months
  • Prevalence of positive cases (PCR and/or serological positive)
    • Time Frame: 3 months

Participating in This Clinical Trial

Inclusion Criteria

  • patients with covid 19 symptoms – patients who had a contact with a person PCR Covid 19+ Exclusion Criteria:

  • none

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 99 Years

Investigator Details

  • Lead Sponsor
    • Maison de Sante Pluridisciplinaire de Creil
  • Provider of Information About this Clinical Study
    • Principal Investigator: DIMI Svetlane, Dr – Maison de Sante Pluridisciplinaire de Creil
  • Overall Contact(s)
    • Svetlane DIMI, M.D, +33650002085, svetlane.dimi@sfr.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.